How should cancer presenting as a malignant pleural effusion be managed?

被引:20
作者
Bonnefoi, H
Smith, IE
机构
[1] ROYAL MARSDEN NHS TRUST,LUNG UNIT,SUTTON SM2 5PT,SURREY,ENGLAND
[2] ROYAL MARSDEN NHS TRUST,MED SECT,SUTTON SM2 5PT,SURREY,ENGLAND
关键词
malignant pleural effusion; unknown primary carcinoma;
D O I
10.1038/bjc.1996.444
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of the study was to review the natural history of patients with a malignant pleural effusion but without obvious evidence of a primary. to assess the value of investigations used to look for a primary and to assess the response to palliative chemotherapy. This was done by a retrospective study of patients' notes at the Lung Unit, Royal Marsden Hospital, Sutton, Surrey. Improvement in tumour-related symptoms (and duration) on chemotherapy was assessed by the patient before the first course of chemotherapy and following each course using simple descriptive criteria as follows: (I) complete disappearance of symptoms (CR); (2) good improvement in symptoms (PR); (3) minor or no change in symptoms (NC); (4) worse symptoms CPD). Pleural effusion objective response (and duration) according to Hamed definition: success defined as a continued absence of reaccumulation of pleural fluid on all follow-up radiographs; any reaccumulation was regarded as a treatment Failure. Overall survival was measured from the date of histological/cytological diagnosis to death. The study included 42 patients. 27 males and 15 females with a median age df 55 years. A primary was found in 15 patients (36%), and considered to be lung cancer. A total of 11/32 (34%) had a thoracic computed tomography (CT) scan with abnormalities compatible with a diagnosis of lung primary. When thoracic CT scan was negative, fibre optic bronchoscopy was always negative (0/13). Abdominal and pelvic CT scan, abdominal ultrasound, pelvic ultrasound and mammograms failed to reveal the primary. Twenty-three patients underwent local treatment and 37 received systemic chemotherapy. A total of 29/37 (78%) patients achieved symptomatic improvement (median duration. 6 months) and 32/37 (86%) an objective response of their pleural effusion on chemotherapy (median duration, 6 months). The median survival of the whole group was 12 months (3-60+ months). In this series the thoracic CT led to a diagnosis of lung primary in 34% of the cases. Other radiological examinations and bronchoscopy were unhelpful. Chemotherapy achieved symptom relief in 75% of patients.
引用
收藏
页码:832 / 835
页数:4
相关论文
共 23 条
[1]   UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN 657 CONSECUTIVE PATIENTS [J].
ABBRUZZESE, JL ;
ABBRUZZESE, MC ;
HESS, KR ;
RABER, MN ;
LENZI, R ;
FROST, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1272-1280
[2]   SYMPTOM RELIEF WITH MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER [J].
ELLIS, PA ;
SMITH, IE ;
HARDY, JR ;
NICOLSON, MC ;
TALBOT, DC ;
ASHLEY, SE ;
PRIEST, K .
BRITISH JOURNAL OF CANCER, 1995, 71 (02) :366-370
[3]   FIBEROPTIC BRONCHOSCOPY AND PLEURAL EFFUSION OF UNKNOWN ORIGIN [J].
FEINSILVER, SH ;
BARROWS, AA ;
BRAMAN, SS .
CHEST, 1986, 90 (04) :516-519
[4]   A COMPARISON OF INTRACAVITARY TALC AND TETRACYCLINE FOR THE CONTROL OF PLEURAL EFFUSIONS SECONDARY TO BREAST-CANCER [J].
FENTIMAN, IS ;
RUBENS, RD ;
HAYWARD, JL .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (09) :1079-1081
[5]  
FENTIMAN IS, 1981, CANCER, V47, P2087, DOI 10.1002/1097-0142(19810415)47:8<2087::AID-CNCR2820470830>3.0.CO
[6]  
2-9
[7]   CISPLATIN-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF POORLY DIFFERENTIATED CARCINOMA AND POORLY DIFFERENTIATED ADENOCARCINOMA OF UNKNOWN PRIMARY SITE - RESULTS OF A 12-YEAR EXPERIENCE [J].
HAINSWORTH, JD ;
JOHNSON, DH ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :912-922
[8]   COMPARISON OF INTRACAVITARY BLEOMYCIN AND TALC FOR CONTROL OF PLEURAL EFFUSIONS SECONDARY TO CARCINOMA OF THE BREAST [J].
HAMED, H ;
FENTIMAN, IS ;
CHAUDARY, MA ;
RUBENS, RD .
BRITISH JOURNAL OF SURGERY, 1989, 76 (12) :1266-1267
[9]   ESTROGEN-RECEPTOR ASSAY IN DIFFERENTIAL-DIAGNOSIS OF ADENOCARCINOMAS [J].
KIANG, DT ;
KENNEDY, BJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 238 (01) :32-34
[10]   PLEURO-PERITONEAL SHUNTING - ALTERNATIVE THERAPY FOR PLEURAL EFFUSIONS [J].
LITTLE, AG ;
KADOWAKI, MH ;
FERGUSON, MK ;
STASZEK, VM ;
SKINNER, DB .
ANNALS OF SURGERY, 1988, 208 (04) :443-450